6-(Trifluoromethyl)pyrid-2-one

We are 6-(Trifluoromethyl)pyrid-2-one CAS:34486-06-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

CAS No: 34486-06-1
Product Name: 6-(Trifluoromethyl)pyrid-2-one
Other Name:
6-(Trifluoromethyl)pyrid-2-one
6-(Trifluoromethyl)pyridin-2(1H)-one
6-Trifluormethyl-2-pyridinol
2-Hydroxy-6-trifluoromethylpyridine
6-(Trifluoromethyl)-2(1H)-pyridinone
6-Trifluoromethylpyridin-2-one
6-Trifluoromethyl-pyridin-2-ol
 
Density: 1.4±0.1 g/cm3
Boiling Point: 265.6±35.0 °C at 760 mmHg
Molecular Formula: C6H4F3NO
Molecular Weight: 163.097
Flash Point: 114.4±25.9 °C
Exact Mass: 163.024506
PSA: 32.86000
LogP: 1.23
Vapour Pressure: 0.0±0.6 mmHg at 25°C
Index of Refraction: 1.457
Storage condition: Room temperature
 
Specification
Appearance: Off-white powder
Assay: ≥98.0%
Water: ≤0.50%
 
Application
Be used as pharmaceutical intermediate and chemical intermediates.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

6-(Trifluoromethyl)pyrid-2-one


Related News: API and raw material are often confused due to the similar usage of the two terms. 3-bromopiridina CAS:626-55-1 The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.12-bromododec-1-eno CAS:99828-63-4 The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.106-41-2 ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.

Related Products
Product Name
BRADYKININ, ACETATE SALT View Details
1-Ethylimidazole View Details
3-fluoro-5-iodo-4-methylbenzoic acid View Details
4-Methyl-3-(trifluoromethyl)aniline manufacturer 2-ethoxynaphthalene-1-carboxylic acid manufacturer Methyl pivaloylacetate manufacturer 4-Methyl-2-(trifluoromethyl)aniline manufacturer 2-Propoxyethyl Chloride manufacturer